Incidence of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Urologic Cancers

Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is a serious adverse event of bone resorption inhibitors (BRIs), such as zoledronic acid and denosumab. Based on the results of phase 3 clinical trials for BRIs, the frequency of ARONJ is 1 to 2%, but the actual frequency is presumed to b...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hinyokika kiyo. Acta urologica Japonica 2022-01, Vol.68 (1), p.1-6
Hauptverfasser:	Kawanishi, Hiroaki, Yokozeki, Hitoshi, Hoshiyama, Akihiro, Watanabe, Hiroki, Funahashi, Yurina, Fujiwara, Maki, Takashima, Yasushi, Shintani, Motoko, Yui, Shumpei, Okumura, Kazuhiro
Format:	Artikel
Sprache:	jpn
Schlagworte:	Bisphosphonate-Associated Osteonecrosis of the Jaw - epidemiology Bone Density Conservation Agents - adverse effects Bone Neoplasms - drug therapy Clinical Trials, Phase III as Topic Humans Incidence Japan - epidemiology Urologic Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!